Effect of Mucosal TRPV1 Inhibition in Allergic Rhinitis

Basic and Clinical Pharmacology and Toxicology

Volumn 110, Issue 3, 2012, Pages 264-268

  Alenmyr, Lisa ^a   Greiff, Lennart ^b   Andersson, Morgan ^b   Sterner, Olov ^a   Zygmunt, Peter M ^a   Högestätt, Edward D ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOPHENYL) 3 [1 (5 TRIFLUOROMETHYL 2 PYRIDINYL) 3 PYRROLIDINYL]UREA; ALLERGEN; CALCIUM; CAPSAICIN; EOSINOPHIL CATIONIC PROTEIN; VANILLOID RECEPTOR 1;

ADULT; ARTICLE; CELL STRAIN HEK293; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; DRUG SYNTHESIS; FEMALE; FLUOROMETRY; HAY FEVER; HUMAN; IN VITRO STUDY; MALE; NASAL LAVAGE; NASAL PRURITUS; NOSE MUCOSA; PEAK NASAL INSPIRATORY FLOW; PRIORITY JOURNAL; PROTEIN INTERACTION; PROVOCATION TEST; SNEEZING; TREATMENT DURATION;

ADULT; CAPSAICIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FLUOROMETRY; HEK293 CELLS; HUMANS; MALE; PYRROLIDINES; RHINITIS, ALLERGIC, SEASONAL; TRPV CATION CHANNELS; UREA; YOUNG ADULT;

EID: 84857355604     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00803.x     Document Type: Article

References (22)

1. Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998;21:531-43.
2. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999;400: 452-7.
3. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997;389:816-24.
4. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 2001;413:203-10.
5. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell 2009;139:267-84.
6. Seki N, Shirasaki H, Kikuchi M, Sakamoto T, Watanabe N, Himi T. Expression and localization of TRPV1 in human nasal mucosa. Rhinology 2006;44:128-34.
7. O'Hanlon S, Facer P, Simpson KD, Sandhu G, Saleh HA, Anand P. Neuronal markers in allergic rhinitis: expression and correlation with sensory testing. Laryngoscope 2007;117:1519-27.
8. Alenmyr L, Hogestatt ED, Zygmunt PM, Greiff L. TRPV1-mediated itch in seasonal allergic rhinitis. Allergy 2009;64:807-10.
9. Shim WS, Tak MH, Lee MH, Kim M, Koo JY, Lee CH et al.TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase. J Neurosci 2007;27:2331-7.
10. Imamachi N, Park GH, Lee H, Anderson DJ, Simon MI, Basbaum AI et al.TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms. Proc Natl Acad Sci U S A 2009;106:11330-5.
11. Johanek LM, Meyer RA, Hartke T, Hobelmann JG, Maine DN, LaMotte RH et al. Psychophysical and physiological evidence for parallel afferent pathways mediating the sensation of itch. J Neurosci 2007;27:7490-7.
12. Rami HK, Thompson M, Stemp G, Fell S, Jerman JC, Stevens AJ et al. Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett 2006;16:3287-91.
13. Gunthorpe MJ, Hannan SL, Smart D, Jerman JC, Arpino S, Smith GD et al. Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor. J Pharmacol Exp Ther 2007;321:1183-92.
14. Chizh BA, O'Donnell MB, Napolitano A, Wang J, Brooke AC, Aylott MC et al. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain 2007;132:132-41.
15. Greiff L, Svensson C, Andersson M, Persson CG. Effects of topical capsaicin in seasonal allergic rhinitis. Thorax 1995;50:225-9.
16. Ahlstrom-Emanuelsson C, Persson CG, Svensson C, Andersson M, Hosszu Z, Akerlund A et al. Establishing a model of seasonal allergic rhinitis and demonstrating dose-response to a topical glucocorticosteroid. Ann Allergy Asthma Immunol 2002;89: 159-65.
17. Greiff L, Pipkorn U, Alkner U, Persson CG. The 'nasal pool' device applies controlled concentrations of solutes on human nasal airway mucosa and samples its surface exudations/secretions. Clin Exp Allergy 1990;20:253-9.
18. Van Rossum JM. Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch Int Pharmacodyn Ther 1963;143:299-330.
19. Kowalski ML, Dietrich-Milobedzki A, Majkowska-Wojciechowska B, Jarzebska M. Nasal reactivity to capsaicin in patients with seasonal allergic rhinitis during and after the pollen season. Allergy 1999;54:804-10.
20. Korsgren M, Andersson M, Borga O, Larsson L, Alden-Raboisson M, Malmqvist U et al. Clinical efficacy and pharmacokinetic profiles of intranasal and oral cetirizine in a repeated allergen challenge model of allergic rhinitis. Ann Allergy Asthma Immunol 2007;98:316-21.
21. Erjefalt I, Persson CG. Inflammatory passage of plasma macromolecules into airway wall and lumen. Pulm Pharmacol 1989;2:93-102.
22. Raphael GD, Igarashi Y, White MV, Kaliner MA. The pathophysiology of rhinitis. V. Sources of protein in allergen-induced nasal secretions. J Allergy Clin Immunol 1991;88:33-42.